VIATRIS INC. Earnings Per Share (Basic)
VIATRIS INC. (VTRS) reported Earnings Per Share (Basic) of -$0.10 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- VIATRIS INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.10.
- VIATRIS INC. earnings per share, basic for the quarter ending 2026-03-31 was $0.15.
- VIATRIS INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.11, a 237.50% decline year-over-year.
- VIATRIS INC. earnings per share, basic for the quarter ending 2025-06-30 was $0.00.
- VIATRIS INC. earnings per share, basic for fiscal 2025 was -$3.00.
- VIATRIS INC. earnings per share, basic for fiscal 2024 was -$0.53, a 1160.00% decline from fiscal 2023.
- VIATRIS INC. earnings per share, basic for fiscal 2023 was $0.05, a 97.08% decline from fiscal 2022.
- VIATRIS INC. earnings per share, basic for fiscal 2022 was $1.71.
| Period end | Earnings Per Share, Basic 1 month | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 11 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.10 10-Q · filed 2026-08-06 | $0.05 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $0.15 10-Q · filed 2026-05-07 | |||||
| 2025-12-31 | -$3.00 10-K · filed 2026-02-26 | |||||
| 2025-09-30 | -$0.11 10-Q · filed 2025-11-06 | -$0.11 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.70 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | -$2.58 10-Q · filed 2026-08-06 | ||||
| 2025-03-31 | -$2.55 10-Q · filed 2026-05-07 | |||||
| 2024-12-31 | -$0.53 10-K · filed 2026-02-26 | |||||
| 2024-09-30 | $0.08 10-Q · filed 2025-11-06 | -$0.19 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.10 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$0.27 10-Q · filed 2025-08-07 | -$0.18 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | $0.10 10-Q · filed 2025-05-08 | |||||
| 2023-12-31 | $0.05 10-K · filed 2026-02-26 | |||||
| 2023-09-30 | $0.28 10-Q · filed 2024-11-07 | $0.50 derived: net income ÷ weighted average shares · filed 2024-11-07 | $0.68 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $0.22 10-Q · filed 2024-08-08 | $0.41 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | $0.19 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | $1.71 10-K · filed 2025-02-27 | |||||
| 2022-09-30 | $0.29 10-Q · filed 2023-11-08 | $0.55 derived: net income ÷ weighted average shares · filed 2023-11-08 | $0.88 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $0.26 10-Q · filed 2023-08-07 | $0.59 10-Q · filed 2023-08-07 | ||||
| 2022-03-31 | $0.33 10-Q · filed 2023-05-08 | |||||
| 2021-12-31 | -$1.05 10-K · filed 2024-02-28 | |||||
| 2021-09-30 | $0.26 10-Q · filed 2022-11-07 | $0.03 derived: net income ÷ weighted average shares · filed 2022-11-07 | -$0.83 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | -$0.23 10-Q · filed 2022-08-08 | -$1.09 10-Q · filed 2022-08-08 | ||||
| 2021-03-31 | -$0.86 10-Q · filed 2022-05-09 | |||||
| 2020-12-31 | -$1.11 10-K · filed 2023-02-27 | |||||
| 2020-09-30 | $0.36 10-Q · filed 2021-11-08 | $0.44 derived: net income ÷ weighted average shares · filed 2021-11-08 | $0.48 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | $0.08 10-Q · filed 2021-08-09 | $0.12 10-Q · filed 2021-08-09 | ||||
| 2020-03-31 | $0.04 10-Q · filed 2021-05-10 | |||||
| 2020-03-29 | $0.00 10-Q · filed 2020-05-12 | |||||
| 2019-12-31 | $0.00 10-K · filed 2020-05-07 | $0.03 10-K · filed 2022-02-28 | ||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-12 | |||||
| 2018-12-31 | $0.69 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |